Access to Advanced Health Institute
Nonprofit biotech research institute focused on developing affordable, field‑ready vaccine technologies and adjuvant formulations for global health. AAHI advances thermostable vaccine presentations, adjuvant platforms, and delivery approaches targeting tuberculosis, malaria, HIV and neglected diseases, and partners with global manufacturers and local stakeholders to enable scalable deployment in low‑resource settings.
Industries
Nr. of Employees
small (1-50)
Access to Advanced Health Institute
Products
Adjuvant formulations portfolio
A diversified portfolio of adjuvant classes formulated for compatibility with protein subunit, inactivated and vector-based vaccines, including TLR agonist-based platforms, saponin-derived adjuvants, alum-adsorbed systems, oil-in-water emulsions, liposomal formulations, nanoparticulate alum and aqueous nanosuspensions.
Spray-dried vaccine platform
Process and platform to convert liquid vaccine formulations into room-temperature-stable dry powders suitable for simplified distribution and potential nasal delivery.
Temperature-stable tuberculosis vaccine candidate
Protein-subunit tuberculosis vaccine candidate formulated for thermal stability and global accessibility (described as a next-generation, temperature-stable TB vaccine candidate).
Adjuvant formulations portfolio
A diversified portfolio of adjuvant classes formulated for compatibility with protein subunit, inactivated and vector-based vaccines, including TLR agonist-based platforms, saponin-derived adjuvants, alum-adsorbed systems, oil-in-water emulsions, liposomal formulations, nanoparticulate alum and aqueous nanosuspensions.
Spray-dried vaccine platform
Process and platform to convert liquid vaccine formulations into room-temperature-stable dry powders suitable for simplified distribution and potential nasal delivery.
Temperature-stable tuberculosis vaccine candidate
Protein-subunit tuberculosis vaccine candidate formulated for thermal stability and global accessibility (described as a next-generation, temperature-stable TB vaccine candidate).
Services
Supply of research formulations and provision of sample materials for preclinical evaluation.
Partnerships to assess antigen‑adjuvant combinations in preclinical models and in vitro assays.
Formulation development for novel immunostimulatory compounds and custom antigen compatibility work.
Assays to evaluate physical mixing compatibility and innate immune stimulation properties on human cells.
Advisory services covering preclinical study design, clinical trial coordination and regulatory application support.
Supply of research formulations and provision of sample materials for preclinical evaluation.
Partnerships to assess antigen‑adjuvant combinations in preclinical models and in vitro assays.
Formulation development for novel immunostimulatory compounds and custom antigen compatibility work.
Assays to evaluate physical mixing compatibility and innate immune stimulation properties on human cells.
Advisory services covering preclinical study design, clinical trial coordination and regulatory application support.
Expertise Areas
- Adjuvant research and formulation
- Thermostable vaccine formulation and delivery
- Vaccine platform development for neglected diseases
- Preclinical assay development and in vitro immune testing
Key Technologies
- Spray-drying
- Lyophilization
- Oil-in-water emulsion formulation
- Liposomal formulation
News & Updates
Organization relocated operations to serviced, move-in-ready laboratory spaces at CoLabs within the 222 Fifth life sciences building to enhance research capacity and collaboration.
Press release describing partnership activities to strengthen global vaccine manufacturing and accelerate access to lifesaving vaccines (partnership announced August 2025).
Blog article explaining the role of adjuvants in vaccine efficacy, manufacturability, and stability, and summarizing formulation platforms used to enhance immune responses.
Organization relocated operations to serviced, move-in-ready laboratory spaces at CoLabs within the 222 Fifth life sciences building to enhance research capacity and collaboration.
Press release describing partnership activities to strengthen global vaccine manufacturing and accelerate access to lifesaving vaccines (partnership announced August 2025).
Blog article explaining the role of adjuvants in vaccine efficacy, manufacturability, and stability, and summarizing formulation platforms used to enhance immune responses.